SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-007481
Filing Date
2024-05-09
Accepted
2024-05-09 09:05:58
Documents
85
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20240331x10q.htm   iXBRL 10-Q 2129307
2 EX-31.1 btai-20240331xex31d1.htm EX-31.1 17373
3 EX-31.2 btai-20240331xex31d2.htm EX-31.2 17592
4 EX-32.1 btai-20240331xex32d1.htm EX-32.1 10353
5 EX-32.2 btai-20240331xex32d2.htm EX-32.2 8786
6 GRAPHIC btai-20240331x10q006.jpg GRAPHIC 83867
7 GRAPHIC btai-20240331x10q007.jpg GRAPHIC 73166
  Complete submission text file 0001558370-24-007481.txt   8657209

Data Files

Seq Description Document Type Size
8 EX-101.SCH btai-20240331.xsd EX-101.SCH 52624
9 EX-101.CAL btai-20240331_cal.xml EX-101.CAL 43959
10 EX-101.DEF btai-20240331_def.xml EX-101.DEF 241365
11 EX-101.LAB btai-20240331_lab.xml EX-101.LAB 498022
12 EX-101.PRE btai-20240331_pre.xml EX-101.PRE 394345
89 EXTRACTED XBRL INSTANCE DOCUMENT btai-20240331x10q_htm.xml XML 1214427
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 24928923
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)